Evaluation of di-sansalvamide A derivatives: Synthesis, structure-activity relationship, and mechanism of action

Journal of Medicinal Chemistry

Volumn 52, Issue 24, 2009, Pages 7927-7930

  Alexander, Leslie D ^a   Sellers, Robert P ^a   Davis, Melinda R ^a   Ardi, Veronica C ^a   Johnson, Victoria A ^a   Vasko, Robert C ^a   McAlpine, Shelli R ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DI SANSALVAMIDE A DERIVATIVE; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DRUG DELIVERY SYSTEMS; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73249150734     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901566c     Document Type: Article

References (19)

1. Belofsky, G. N.; Jensen, P. R.; Fenical, W. Sansalvamide: a new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium. Tetrahedron Lett. 1999, 40, 2913-2916.
2. Hadden, M. K.; Blagg, B. S. J. Dimeric approaches to anti-cancer chemotherapeutics. Anti-Cancer Agents Med. Chem. 2008, 8, 807-816.
3. Yang, S.-T.; Kim, J. I.; Shin, S. Y. Effect of dimerization of a β-turn antimicrobial peptide, PST13-RK, on antimicrobial activity and mammalian cell toxicity. Biotechnol. Lett. 2009, 31, 233-237.
4. Davis, M. R.; Styers, T. J.; Rodriguez, R. A.; Pan, P.-S.; Vasko, R. C.; McAlpine, S. R. Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles. Org. Lett. 2008, 10, 177-180.
5. Singh, E. K.; Sellers, R. P.; Alexander, L. D.; McAlpine, S. R. Conformational based design of macrocycles as antitumor agents. Curr. Opin. Drug Discovery Dev. 2008, 11, 544-552.
6. Starzl, T. E.; Klintmalm, G. B.; Porter, K. A.; Iwatsuki, S.; Schroter, G. P. Liver transplantation with use of cyclosporin a and prednisone. N. Engl. J. Med. 1981, 305, 266-269.
7. Le Tourneau, C.; Raymond, E.; Faivre, S. Reports of Clinical Benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. Curr. Pharm. Des. 2007, 13, 3427-3429.
8. Styers, T. J.; Rodriguez, R. A.; Pan, P.-S.; McAlpine, S. R. Highyielding macrocyclization conditions used in the synthesis of novel sansalvamide A derivatives. Tetrahedron Lett. 2006, 47, 515-517.
9. Heller, M.; Sukopp, M.; Tsomaia, N.; John, M.; Mierke, D. F.; Reif, B.; Kessler, H. The conformation of cyclo(-Dpro-ala-) as a model for cyclic pentapeptides of the DL type. J. Am. Chem. Soc. 2006, 128, 13806-13814.
10. Neckers, L. Hsp90 inhbitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-S61.
11. Nemoto, T.; Ohara-Nemoto, Y.; Ota, M.; Takagi, T.; Yokoyama, K. Mechanism of dimer formation of the 90-kDa heat shock protein. Eur. J. Biochem. 1995, 233, 1-8.
12. Matei, D.; Satpathy, M.; Cao, L.; Lai, Y.-K.; Nakshatri, H.; Donner, D. B. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J. Biol. Chem. 2007, 282, 445-453.
13. Usmani, S. Z.; Bona, R.; Li, Z. H. 17AAGfor HSP90 iInhibition in cancer;from bench to bedside. Curr. Mol. Med. 2009, 9, 654-664.
14. Koga, F.; Kihara, K.; Neckers, L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 2009, 29, 797-807.
15. Barginear, M. F.; Van Poznak, C.; Rosen, N.; Miodi, S.; Hudis, C. A.; Budman, D. R. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr. Cancer Drug Targets 2008, 8, 522-535.
16. Chakraborty, A.; Koldobskiy, M. A.; Sixt, K. M.; Juluri, K.; Mustafa, A. K.; Snowman, A. M.; van Rossum, D. B.; Patterson, R. L.; Snyder, S. H. Hsp90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1134-1139.
17. Donnelly, A.; Blagg, B. S. J. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 2008, 15, 2702-2717.
18. Heath, E. I.; Hillman, D. W.; Vaishampayan, U.; Sheng, S.; Sarkar, F.; Harper, F.; Gaskins, M.; Pitot, H. C.; Tan, W.; Ivy, S. P.; Pili, R.; Carducci, M. A.; Erlichman, C.; Liu, G. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormonerefractory metastatic prostate cancer. Clin. Cancer Res. 2008, 14, 7940-7946.
19. Solit, D. B.; Osman, I.; Polsky, D.; Panageas, K. S.; Daud, A.; Goydos, J. S.; Teitcher, J.; Wolchok, J. D.; Germino, F. J.; Krown, S. E.; Coit, D.; Rosen, N.; Chapman, P. B. Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14, 8302-8307.